Interview with Katie Thurston, The Bachelorette & Women’s Health Advocate

Dr. Thais Aliabadi and Mary Alice Haney sat down with Katie Thurston to talk frankly about a life that changed in an instant: a breast lump she first noticed in her 30s that led to a cancer diagnosis, a misread pathology report, a transfer of care, fertility preservation, a clinical trial, and ultimately a stage 4, hormone receptor positive, HER2 negative diagnosis. Katie brings blunt honesty, humor, and fierce advocacy to every part of her story. We kept the conversation in a question-and-answer format so you can follow her timeline and takeaways easily.

Table of Contents

• Outline
• What we learned from Katie
• FAQ
• Final thoughts we keep with us

Outline

• Diagnosis and the importance of a second opinion
• How she first noticed the lump and early steps
• Pathology mix-up and treatment pivot to targeted therapy
• Fertility preservation, IVF, and genetic testing
• Living with stage 4 disease: scans, medications, and outlook
• Online rumors, advocacy, and the Booby Broadcast community
• Personal life: relationships, the Bachelorette experience, and family planning
• Practical takeaways and what to do if you or someone you love gets a diagnosis
• FAQ

Tell us, Katie—what is your diagnosis today and how do you describe it?

We know Katie describes her diagnosis as hormone receptor positive, HER2 negative, stage 4 breast cancer. That string of words carries a lot of clinical meaning. Hormone receptor positive means the tumor grows in response to estrogen and/or progesterone. HER2 negative means the tumor does not overexpress the HER2 protein, which affects aggressiveness and which drugs will work. Stage 4 means the cancer has metastasized — in Katie’s case the liver was involved — which makes the condition a chronic but treatable disease in many cases.

Walk us through that first diagnosis and why a second opinion mattered so much.

At first, Katie was told she was stage 3, triple positive (meaning ER positive, PR positive, HER2 positive). Four weeks later, at Columbia, after transferring care, her biopsy and re-review of the prior pathology showed HER2 negative and stage 4. That difference changed treatment completely. Chemotherapy regimens, targeted therapies, and prognosis vary by these biomarkers. Katie stresses the importance of getting a second opinion because labs and pathology reads can occasionally be misinterpreted or require a different testing method.

We want to underscore that pathology is the backbone of cancer treatment decisions. A single line on a path report — HER2 positive versus negative — can mean the difference between starting one set of medications and another. Katie described being 24 hours away from chemotherapy with a port already placed when the retesting arrived. The lesson: if something doesn’t sit right, or your treatment plan seems mismatched, ask for another review. Ask for the original slides to be reread. Take a breath and get a second opinion at a major center if possible.

What did you feel physically when you first noticed the problem?

Katie found a lump. She had felt a lump years earlier that was a benign cyst and was treated with an excisional biopsy. This time, she assumed it might be the same. She ignored it initially. Full-body scans are promoted online and are even labeled as scar tissue. Despite that, the lump persisted, and eventually she sought evaluation. The ultrasound felt different, the technician was unusually quiet, and she remembers the emotional moment when she realized this might be something serious.

You mentioned a misread on the pathology report — how common is that, and what can people do about it?

Misreads on pathology are uncommon but not impossible. Cancer pathology involves different tests and sometimes multiple ways of staining or analyzing tissue. Katie’s team at Columbia requested a new biopsy and retested the old one, confirming HER2 negative. Different laboratories sometimes use different testing protocols, and specialist centers may have more expertise or more sensitive assays.

Practical steps if you suspect a discrepancy:

• Ask for your pathology report and a copy of the slides.
• Request an independent second read by a breast pathology expert or at a comprehensive cancer center.
• Discuss confirmatory tests like immunohistochemistry or fluorescence in situ hybridization when HER2 is in question.
• File a request for review or a medical grievance if results are inconsistent.

How did the treatment plan change once the diagnosis was clarified?

Once Katie was confirmed to be hormone receptor positive and HER2 negative, she switched from a chemotherapy plan to targeted therapy. She is on a CDK4/6 inhibitor called Kisqali alongside endocrine suppression. The change meant fewer broad cytotoxic drugs and a strategy that targets the tumor’s specific biology.

Within three months, the scans showed shrinkage in both the breast lesion and the liver deposits — a sign that the targeted regimen is working. Her liver lesions were so small they were nearly undetectable on the follow-up imaging, which allowed her team to forgo local liver-directed therapies like ablation.

Tell us about fertility preservation — why did you do IVF, and how did that fit into early treatment?

Katie opted for a fast-track IVF cycle before starting systemic therapy because many chemotherapy agents can damage ovarian reserve and future fertility. She and her husband completed a 10-day stimulation and successfully created two embryos. Those embryos are preserved for future use, likely via surrogacy, given her current medical plans.

Fertility preservation often requires a rapid but careful balance: ovarian stimulation increases estrogen levels temporarily, which can feel counterintuitive when treating hormone-sensitive cancers. Still, many oncologists recommend fast-track retrieval combined with ovarian suppression strategies to minimize risk. The decision to freeze embryos is intensely personal and depends on age, partner status, insurance coverage, and urgency of starting cancer therapy.

How did you find out about the ATM genetic mutation, and why does that matter?

Katie discovered she carries an ATM mutation during the genetic workup that accompanied IVF. The ATM mutation increases lifetime breast cancer risk — estimates vary, but Katie and her care team discussed it as a substantial increase compared with the general population and lower than BRCA1/2, but still high enough to change screening strategies.

Why this matters:

• Family members can be offered testing to determine whether they carry the mutation and therefore need altered screening.
• For mutation carriers, breast imaging can be started earlier — often by age 25 to 30, depending on the gene and family history — rather than waiting until 40.
• Some mutations also raise risks for cancers in other organs, so a tailored surveillance plan is created with genetics and oncology teams.

Katie’s family history included a grandfather with pancreatic cancer, and pancreatic and prostate cancers can be associated with certain hereditary mutations. That is one reason genetic testing is recommended sooner rather than later if there is a family history of uncommon cancers or multiple relative cancers.

Why should young people, especially under 40, pay attention to breast health?

Katie was 34 when she was diagnosed. She emphasizes that breast cancer is not only a disease of older women. The incidence in younger age groups has been rising. Signs and symptoms matter more than age alone. If you feel a new lump, see a clinician. Don’t let the standard population screening age (often 40) lull you into inaction if you or your family history suggests otherwise.

Key points:

• Self-awareness is essential. Know how your breasts normally look and feel.
• If you notice changes — lumps, dimpling, discharge, persistent pain, or skin changes — get evaluated regardless of age.
• Family history matters across both male and female relatives. Pancreatic or prostate cancer in the family can be relevant.
• Genetic testing can reclassify your lifetime risk and move your screening timeline earlier if indicated.

How did you land on a clinical trial, and how did that change the workup?

Katie chose a clinical trial at Columbia instead of immediate standard-of-care chemotherapy. As part of the trial workup, she was granted a PET scan, which revealed metastatic disease and changed her staging to stage 4. Large medical centers and academic hospitals often have access to trials. If you have a complex diagnosis, consider asking whether trials might be an option — they can offer access to novel therapies and more extensive baseline imaging in some cases.

What is a typical monitoring schedule for someone in Katie’s situation?

Katie described a close follow-up routine. She has monthly blood work, a monthly leuprolide shot to suppress ovarian function, and imaging — PET scan and MRI — every three months. That cadence can be intense, but it allows the team to see early signs of response or progression and to modify therapy promptly.

Expectations with stage 4, hormone receptor-positive disease:

• Ongoing systemic therapy that can be paused only with clinical justification.
• Frequent imaging intervals early on to confirm response to new treatments.
• Long-term chronic management with periodic reassessment of goals (disease control, quality of life, endpoints like no evidence of disease when possible).

Are people with stage 4 disease ever considered for surgery, like a double mastectomy?

There is no single answer. For some people with limited metastatic sites and excellent systemic control, local surgery may be discussed for symptom control or in clinical trials. For others, the data do not clearly show a survival benefit. Katie planned a double mastectomy pending scans, but she decided to delay surgery because surgical recovery requires a pause in her oral medication for several weeks. When therapy is working and disease burden is shrinking, many patients and doctors opt to continue systemic therapy and wait for a sustained deep response before pursuing elective surgery.

The decision is highly individualized and depends on:

• Extent and location of metastatic disease
• Response to systemic therapy
• Genetic risk and patient preference
• Potential benefits for symptom control or prevention

How did social media and online rumors affect you, and why did you decide to be public about your journey?

Katie has faced cruel clickbait rumors claiming she was dead. That experience highlights two things: the toxic potential of online misinformation and the emotional labor of living a public medical journey. Despite that, Katie chose transparency because she wanted to help other women learn, act early, and make informed decisions. Her public presence has become a platform for education on genetic testing, earlier screening, and community support.

She explained that being vocal is both personal and strategic: it helps millions of women and also gives families access to critical information that might change outcomes in the next generation.

What is the Booby Broadcast, and why is it important?

The Booby Broadcast is an Instagram broadcast channel Katie created to build community, answer questions, and connect people living with breast cancer or navigating risk. It functions like an internal Reddit thread where people can post their diagnoses, resources, and offers of support. Tens of thousands of people are part of the channel, and it includes medical professionals, survivors, and patients at various stages.

The Booby Broadcast demonstrates the power of peer-to-peer support. It allows people to share practical tips, ask for referrals, and feel less alone in the bewildering early phase after diagnosis.

How has the Bachelorette experience intersected with your health journey and relationships?

Katie was the Bachelorette before these medical events. She reflected on how reality TV changed dating dynamics and introduced the practical question of whether suitors were there for the right reasons once social media visibility entered the equation. She met her husband outside the Bachelor world through her interest in comedy, and he became a central support during the diagnosis. They moved fast — first date in May, engaged in August, diagnosed in January, and married in March — and their relationship endured the acute stress of early treatments.

Her message about relationships is pragmatic: find a partner who can be matched to you across many domains — emotional availability, financial stability, career goals, and willingness to cope with public life. That alignment makes life during illness much easier.

What practical advice does Katie give to women who are newly diagnosed or worried about breast changes?

Katie offered several straightforward tips:

• Don’t wait because of age. If you notice a lump or change, seek evaluation right away.
• Ask for genetic counseling and testing if you have a family history of cancer, including pancreatic or prostate cancers in male relatives.
• Get a second opinion — especially if test results or treatment plans feel inconsistent.
• Consider fertility preservation early if you plan to have biological children.
• Find your community. Let other people help. Peer support is essential.
• Advocate for thorough testing and make sure your pathology has been reviewed by specialists when needed.

What we learned from Katie

We walked away with concrete takeaways and a renewed sense of urgency about breast health:

• Breast cancer is not one-size-fits-all. Subtypes and biomarkers determine treatment.
• A second opinion can save lives or at least change the course of therapy.
• Genetic testing can radically change screening timelines. If you qualify, get tested early.
• Fertility preservation is feasible in a short timeframe and should be discussed at the outset.
• Community and honest storytelling heal. Katie turned her platform into a resource for tens of thousands of women.

FAQs

At what age should genetic testing be considered if I have a family history of cancer?

If you have a family history of certain cancers — pancreatic, male prostate cancer, early-onset breast cancer, or multiple relatives with cancer — genetic testing should be discussed with your provider by age 25. Insurance often covers testing when there is an actionable family history. Detecting high-risk mutations earlier can move screening timelines up and allow for surveillance that might catch disease at an earlier, more treatable stage.

Does being stage 4 mean no chance for long-term control or remission?

Stage 4 indicates metastatic disease, which historically has been considered incurable, but advances in targeted therapy, endocrine therapy, immunotherapy, and surgical approaches have dramatically extended survival for many people. Some patients achieve a status where no disease is visible on scans, often called no evidence of disease. The term “forever diagnosis” reflects the current model, but individualized care, clinical trials, and emerging therapies continue to change the outlook. Many people with stage 4 disease live years with a good quality of life.

Why did Katie pursue IVF before starting cancer treatment?

Chemotherapy can impair fertility by damaging ovarian reserve. By doing IVF first, Katie preserved embryos for future use. A fast-track stimulation and retrieval are possible in a short window before systemic therapy begins. Discuss fertility preservation with your oncologist and a reproductive endocrinologist as soon as cancer is diagnosed if you want biological children later.

How can I know if I need an earlier mammogram or breast MRI?

Standard screening often begins at age 40 for average-risk individuals, but if your lifetime risk is 20% or higher — because of genetic mutations, strong family history, or prior chest radiation — earlier imaging starting in the 20s or 30s might be recommended. A genetic counselor or your primary care doctor can help determine your risk and recommend individualized imaging, such as a mammogram, ultrasound, or MRI.

What should I do if I find conflicting information or feel like my care team is missing something?

Ask for clarification and documentation. Request a second pathology read or referral to a specialist center. If treatment options seem limited, ask whether clinical trials are available. If you feel dismissed, bring a family member or advocate to appointments. Your voice matters. A good care team will welcome questions and help you navigate options.

How do I protect myself from online misinformation and rumors about health?

Rely on primary sources: medical records, direct communication from clinicians, and reputable institutions. If a sensational claim circulates online, check the source and cross-reference with official statements. Set boundaries around social media for your mental health. If you are a public figure, ask trusted friends or representatives to monitor false claims and report them when necessary.

Final thoughts we keep with us

Katie’s story is a powerful reminder that health care is personal, complicated, and often imperfect. Misreads happen, tests evolve, and good outcomes depend on advocacy, high-quality care, and community support. We leave this conversation with a few practical commitments we all should act on: know your body, ask questions, get the right genetic screening when family history suggests it, and lean into real communities for support. Katie’s openness has already changed lives by teaching women to act sooner and ask for better care.

If you want to connect with Katie, she is active on Instagram at @thekatiethurston and invites people to join her Booby Broadcast for community support and resources.

This article was created from the video Katie Thurston Opens Up About Her Stage 4 Breast Cancer & The Online Rumors | SHE MD for Dr. Thais Aliabadi’s website.